QLC7401 injection

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Heterozygous Familial Hypercholesterolemia (HeFH)Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C

Phase 1

Pharmacokinetics and Pharmacodynamics Study

Not yet recruitingNCT07074236

Qilu Pharmaceutical Co., Ltd.Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C

Start: 2025-07-31End: 2026-01-31Target: 48Updated: 2025-07-24

Phase 3

QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Not yet recruitingNCT07450378

Qilu Pharmaceutical Co., Ltd.Heterozygous Familial Hypercholesterolemia (HeFH)

Start: 2026-05-01End: 2028-07-01Target: 120Updated: 2026-03-04